Edesa Biotech provides update on EB06 clinical study

Edesa Biotech (EDSA) provided an update on preparations and reaffirmed enrollment timeline guidance for its Phase 2 clinical study of EB06 in moderate-to-severe nonsegmental vitiligo. The announcement coincides with the company’s sponsorship and participation at the Global Vitiligo Foundation annual scientific symposium in Denver, Colorado. Edesa reported that it has selected JSS Medical Research, Inc. to act as its clinical research organization for the proof-of-concept study, and outreach to potential clinical sites and investigators has begun. Based on this progress, the company reaffirmed its previous guidance that site activations and patient recruitment are expected to begin mid-2026. Enrollment is anticipated to commence first at investigational sites in Canada, where Edesa’s clinical trial application was approved. As planned, Edesa’s Phase 2 study will evaluate the safety and efficacy of EB06 versus placebo in adults with non-segmental vitiligo. Patients will receive intravenous infusions of either EB06 or placebo during the treatment period, followed by a follow-up period.